Latest Press Releases
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
- 85% (n=29/34) of Evaluable Patients Achieved Complete Response at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial - May 1, 2023, 8:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. announced updated data from the CORE-001...
New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting
April 10, 2023, 8:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated...
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., December 27, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P....
Upcoming Conferences
CG in the News
ENDPOINTS NEWS
May 24, 2023
Endpoints 20 under 40 – Arthur Kuan is featured
ONCOLOGY TUBE
May 23, 2023
Pembrolizumab combined with CG0070. How can this help patients with NMIBC? Roger Li
